small molecule

ARBLI

LOSARTAN POTASSIUM

Loss of exclusivityOctober 2041latest FDA-listed patent expiry
CompanySCIENTURE LLC

Drug detail

Brand nameARBLI
Active ingredientLOSARTAN POTASSIUM
Strength10MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Listed patents

PatentExpiresType
12156869October 2041product
12605365October 2041product
11890273October 2041product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARBLI patent cliff — loss of exclusivity October 2041 | CliffBio